Forward-Looking Statements Note: All statements in this presentation that are not historical facts should be considered as Forward-Looking Statements within the.
Full Year 2023Revenue was $2.463 Billion, up 0.8 PercentOperating Income was $118.0 Million or 4.8 Percent of RevenueNet Income was $18.3 Million or 0.7 Percent of RevenueAdjusted EBITDA was $271.5.
Exceeded revised guidance on Free Cash Flow before Growth and achieved high end of Adjusted EBITDA revised guidance
Delivered exceptional operational performance through volatile summer and.
/PRNewswire/ Avanos Medical, Inc. (NYSE: AVNS) today reported fourth quarter and full-year 2023 results. "We were very pleased with the overall execution on.
Fourth Quarter Earnings Per Share of $1.91 and Adjusted Earnings Per Share1 of $2.60, Above Midpoint of Previous GuidanceFourth Quarter Sales of $9.4 Billion, Reported Sales Up 3%, Organic1 Sales Up.